Kidney Cancer Clinical Trial

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Summary

This phase I trial studies how well a ketogenic dietary intervention works to improve response to immunotherapy in patients with melanoma and kidney cancer that has spread from where it first started (primary site) to other places in the body (metastatic). A ketogenic diet (KD) means eating fewer carbohydrates and more fats. The purpose is to use ketones (normal breakdown from fat) instead of glucose (sugar) as an energy source. Researchers want to see whether a ketogenic diet can improve tumor response in patients receiving immune checkpoint inhibitors (ICI). ICI are newer treatment options that help the immune system better fight some cancers. Following a KD may improve tumor response in patients with metastatic melanoma and metastatic kidney cancer treated with ICI.

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To evaluate the safety and feasibility of establishing a ketogenic dietary intervention trial with longitudinal biospecimen collection in the Ohio State University Comprehensive Cancer Center (OSUCCC) cutaneous and genitourinary oncology clinics.

EXPLORATORY OBJECTIVE:

I. To assess whether the microbiome (binary, high versus [vs] low diversity) mediates the relationship between time in ketosis (days with peripheral blood beta-hydroxybutyric acid [BHB] > 0.5 mM) and tumor size over the course of treatment.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo a ketogenic dietary intervention with personalized coaching from a dietician about the KD, which includes extensive educational and ongoing support on the KD and continuous ketone monitoring by talking to a dietician directly, with the ability to text a dietician at any time and expect a response within 12 hours over 24weeks. Patients also undergo daily blood glucose and ketone monitoring, undergo computed tomography (CT), undergo blood sample collection and may undergo stool sample collection on the study.

ARM II: Patients follow a standard of care diet on the study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Males and females, age >= 18 years
Clinical site A will include patients with confirmed diagnosis of metastatic melanoma (including those with brain metastases) receiving first line treatment with combination nivolumab and ipilimumab or single agent ipilimumab, nivolumab, pembrolizumab
Clinical site B will include patients with confirmed diagnosis of metastatic renal cell carcinoma (RCC) (including those with brain metastases) receiving first line treatment with combination nivolumab and ipilimumab or single agent PD-1 inhibitor (e.g., nivolumab, pembrolizumab)
Scheduled for imaging every 6 to 12 weeks for metastatic melanoma (MM) and mRCC as is standard of care per National Comprehensive Cancer Network (NCCN) guidelines
Able to read, understand, and provide written informed consent
Willing to provide stool specimen for research studies as outlined in the timeline
Willing to participate in a ketogenic diet (KD)

Exclusion Criteria:

Individuals < 18 years of age
Unable or unwilling to provide consent
Patients with type 1 diabetes mellitus or type 2 diabetes using insulin
Patients who are clinically underweight (body mass index [BMI] < 18.5) at the start of treatment
Other active malignancy (other than adequately treated and cured basal or squamous cell skin cancer, curatively treated in situ disease, or any other cancer from which the patient has been disease free >=5 years)
Currently consuming a low-carbohydrate (< 130 g/day) or ketogenic diet or done so in the last 6-months
Women who are known to be pregnant are excluded. However no additional pregnancy testing out of what would be recommended prior to initiating anti-cancer therapy will be performed solely for this study
Patients currently participating in an interventional or therapeutic clinical trial involving the use of active anti-cancer therapy

Study is for people with:

Kidney Cancer

Estimated Enrollment:

40

Study ID:

NCT06391099

Recruitment Status:

Not yet recruiting

Sponsor:

Ohio State University Comprehensive Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Ohio State University Comprehensive Cancer Center
Columbus Ohio, 43210, United States More Info
Marium Husain, MD, MPH
Contact
614-366-6567
[email protected]
Marium Husain, MD, MPH
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Estimated Enrollment:

40

Study ID:

NCT06391099

Recruitment Status:

Not yet recruiting

Sponsor:


Ohio State University Comprehensive Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.